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The interactions of the tributyl, triethyl and trimethyllead compounds with energized mitochondria have been investigated in this
paper. It has been shown that the (alkyl)3Pb–Cl compounds induce swelling in mitochondria suspended in a sucrose medium. The phe-
nomenon is more marked the higher the lipophilicity and occurs in the following order: (Bu)3Pb > (Et)3Pb > (Me)3Pb. As swelling is
inhibited by cyclosporine, this suggests that the swelling is due to the opening of a trans-membrane pore (MTP pore) in the mitochondria.
As this pore can be responsible for the inhibition of the ATP synthesis, and, consequently for cell death, the opening of the pore could be
one of the reasons for the toxicity of the (alkyl)3Pb–X compounds.
 2007 Elsevier Inc. All rights reserved.
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lead have been widely utilized as antiknock compounds
in fuels. Their presence in the environment gives rise to
environmental problems, since the organolead compounds
are very toxic, and the nervous system is the preferred tar-
get [1–3]. However, the persistence of these (alkyl)4Pb com-
pounds in the environment is not particularly high, since
they are metabolized into the trialkyl (alkyl)3Pb–X com-
pounds [4] and the toxicity is probably due to the presence
of the latter [4,5].
The toxicity of the trialkyllead compounds was studied
‘‘in vitro’’, in order to ﬁnd themolecular, or biological target
responsible for the ‘‘in vivo’’ eﬀects. The mitochondria were
studied in depth as, in many cases, they are responsible for
acute toxic eﬀects [6–10]. This is a consequence of the fact
that the damage to the mitochondria, which produce energy
for the cell (in the form of ATP) induces an equivalent cell
damage. In the case of the (alkyl)3Pb–X compounds, many
mechanisms which could induce ATP synthesis inhibition0162-0134/$ - see front matter  2007 Elsevier Inc. All rights reserved.
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E-mail address: bragadin@unive.it (M. Bragadin).have been proposed. In particular, Aldridge et al. [7]
proposed that the (alkyl)3Pb–X compounds enter the mito-
chondria as (alkyl)3Pb–Cl and are extruded as (alkyl)3Pb–
OH, thus acting as Cl/OH ion exchangers. Alternatively,
Bragadin et al. [6] proposed that the compounds enter the
mitochondrial matrix as (alkyl)3Pb
+ compounds and are
extruded as (alkyl)3Pb–OH, thus giving rise to a cyclic
mechanism which enhances the mitochondrial proton per-
meability. This does not exclude the fact that other mecha-
nisms can induce an energy collapse in mitochondria (ATP
synthesis inhibition).
The aimof this paper is to give evidence that (alkyl)3Pb–X
compounds induce the opening of a trans-membrane pore,
which inhibits ATP synthesis [11,12]. It should be noted that
this is a ‘‘molecular’’, not a toxicological study. However, it
will prove to be useful for a subsequent toxicological study,
where the various molecular eﬀects (mechanisms which
induce ATP synthesis inhibition) are compared, in order to
identify the eﬀect which requires the lowest dose of toxic
compound.
In mitochondria, the free energy arising from the oxida-
tion of the substrates is stored and subsequently utilized, to
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sequence of redox couples: i.e. the mitochondrial respira-
tory chain (RC). The electron ﬂow in the RC is coupled
with a stoichiometric proton extrusion and, since the mito-
chondrial membrane is not permeant to the protons, their
extrusion gives rise to both a DpH and a DW. The sum of
these two terms
DpHþ DW ¼ p:m:f :
is called the proton-motive force (p.m.f.) and in this form,
the energy is stored and subsequently utilized to synthesize
the ATP from the ADP [13]. The crucial factor concerning
this mechanism is that the membrane is not permeant to
the protons. Therefore, it follows that, any mechanism
which induces an enhancement of the proton permeability,
also induces ATP synthesis inhibition.
In recent years, it has been observed that many chemical
compounds induce the opening of large size pores [11,12]
(MTP pores). The size of these pores allows for the passage
of large molecules (molecular mass about 1500 Da [11])
and consequently, of the protons. Therefore, the opening
of an MTP pore implies an inhibition of the ATP synthesis.
The opening of an MTP pore (which is inhibited by means
of Cyclosporine [12]) is evidenced by means of swelling
experiments: if the mitochondria are resuspended in a
sucrose medium, the sucrose does not enter into the matrix,
but, if the opening of the MTP pore is induced, the sucroseFig. 1. Trialkyllead compounds induce the opening of the MTP pore. In A, m
1 mM MgSO4, 2 mM sodium succinate, 0.5 mM EGTA. The ﬁnal conce
concentration of the mitochondria was monitored by means of the Lowry p
indicated in Ref. [18]. After the addition of the mitochondria, the Jenway 6
wavelength of 540 nm. In this condition, the addition of trialkyllead compoun
pore. Each arrow indicates in (a) the addition of 5 lM (methyl)3Pb–Cl, in (b), t
Cl. It is evident that the same phenomenon is monitorable in (a) with a dose no
less than 2 lM (butyl)3Pb. Since the same behaviour appears in B (KCl medium
pore follows the butyl > ethyl > methyl sequence. The dotted line indicates tha
The eﬀect of the Cyclosporine conﬁrms (and is the crucial proof) that the Ab
opening of the MTP pore. For comparison purposes, the eﬀect of 20 lM of p
pore, is shown in (d) [19]. Also in this case, it can be seen that the eﬀect of the C
Absorbance quenching). In B the conditions were the same, but the medium
Hepes–Mops pH 7.4, 1 mM MgSO4, 2 mM sodium succinate, 0.5 mM EGTAenters into the matrix. The entry of the sucrose is accompa-
nied by the entrance of water and, as a consequence of a
colloid osmotic eﬀect, [14] a swelling of the mitochondria
occurs [11–14]. The swelling can easily be monitored spec-
trophotometrically, since it induces an absorbance quench-
ing at 540 nm.
The absorbance quenching of the mitochondrial suspen-
sion induced by (methyl)3Pb–Cl, (ethyl)3Pb–Cl and
(butyl)3Pb–Cl is reported in Fig. 1. This eﬀect is inhibited
by means of Cyclosporine, thus indicating, as with the
other organometallic compounds [15], that the swelling
(which is correlated with the absorbance quenching) is
due to the opening of the MTP pore (and not to other
mechanisms such as the denaturants, which also allow for
the passage of solutes, but the phenomenon is not inhibited
by the presence of Cyclosporine [14]). The swelling depends
on the lipophilicity of the compounds. This implies that the
more lipophilic the compound, the lower the dose neces-
sary to obtain the same eﬀect. Therefore, the eﬃcacy is in
the following order:
butyl > ethyl > methyl:
For comparison purposes, the eﬀect of phenylarsine
oxide, a typical inducer of the opening of the MTP pore,
is shown in Fig. 1d [15,19].
The swelling of mitochondria, induced by the
(alkyl)3Pb–X compounds has already been observed [7,8],edium composition (2.5 ml): 0.25 M sucrose, 10 mM Hepes–Mops pH 7.4,
ntration of mitochondria, ﬁnal concentration: 0.5 mg/ml. The protein
rocedure [17]. The mitochondria were prepared following the procedure
400 spectrophotometer was reset at zero absorbance, with an operative
ds causes an Absorbance quenching, suggesting the opening of the MTP
he addition of 2 lM (ethyl)3Pb–Cl, in (c), the addition of 1 lM (butyl)3Pb–
less than 20 lM (methyl)3Pb, in (b) no less than 8 lM (ethyl)3Pb, in (c), no
), this leads to the conclusion that the capacity to induce the opening of the
t the same experiment was performed in the presence of 1c Cyclosporine.
sorbance quenching induced by the trialkyl lead compounds is due to the
henylarsine oxide (PhAs), which is an inducer of the opening of the MTP
yclosporine (dotted line) is the inhibition of the opening of the pore (with
composition was diﬀerent. Medium composition B: 0.125 M KCl, 10 mM
.
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gested that the swelling was due to the exchange between
(alkyl)3Pb–OH and (alkyl)3Pb–Cl in the mitochondrial
matrix. However, at the time when this type of mechanism
was presumed to be the correct one, the existence of a
transmembrane pore (and its Cyclosporine sensitivity)
had not yet been individualized.
Our interpretation is further supported by the fact that
the concentrations of trialkyllead are too low to justify a
swelling and, above all, by the fact that our medium con-
tains sucrose (Fig. 1A), while chloride was absent (in the
experiments of Fig. 1A) Both of these factors are not com-
patible with an Cl/OH ion exchange.
We have excluded that the observed swelling could be
due to the concomitant presence of Pb2+ and Ca2+ [21]
as contaminants or, in the case of Pb2+ that it was created
by reduction of the Pb4+ of the alkylcompounds by means
of the mitochondrial respiratory chain, since we operated
in a Ca2+ free medium. In addition, the results are the same
if 0.5 mM of EGTA (Fig. 1 legend) is present in the
medium. It has been observed that EGTA reverses the pos-
sible eﬀects of Ca2+ and/or Pb2+ as inducers of the opening
of the pore [21].
In addition, the opening of the pore can explain certain
phenomena observed in the cells, such as the Ca2+ release
which occurs in the presence of micromolar concentrations
of (alkyl)3Pb–X compounds [16].
Although this is not a toxicological work, it should be
noted that the toxicity of the organometals in many, (but
not all) whole organisms, generally follows the lipophilicity
order as it did in our ‘‘in vitro’’ experiments [20]. This con-
sideration, together with the most relevant data regarding
the opening of the cyclosporine-sensitive pore (MTP),could oﬀer an explanation for the molecular causes of this
type of toxicity.References
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